BMS1P20

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, BMS1P20 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated BMS1P20 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BMS1P20 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BMS1P20 expression acts as an unfavorable survival marker.

HNSC are the cancer types where BMS1P20 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
HNSCDFSMedianAll0.1220.696<.00145view →
Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

BMS1P20–HNSC (DFS)

Kaplan–Meier survival curve for BMS1P20 mutant vs wild-type samples in HNSC.

Open the HNSC breakdown →

Exploration